-
公开(公告)号：US08673299B2
公开(公告)日：2014-03-18
申请号：US13207774
申请日：2011-08-11
IPC分类号： A61K39/395 , C07K16/18 , C07K16/24
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/52 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2319/00
摘要： The invention relates to fully human monoclonal antibodies, and fragments thereof, that bind to the chemokine Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES, CCL5), thereby modulating the interaction between RANTES and one of more of its receptors, such as, e.g., CCR1, CCR3, CCR4 and CCR5, and/or modulating the biological activities of RANTES. The invention also relates to the use of these or any anti-RANTES antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder.
摘要翻译： 本发明涉及完全人单克隆抗体及其片段，其结合活化时调节的趋化因子，表达正常T细胞和分泌型（RANTES，CCL5），从而调节RANTES与其多个受体之一的相互作用， 例如CCR1，CCR3，CCR4和CCR5，和/或调节RANTES的生物学活性。 本发明还涉及这些或任何抗RANTES抗体在预防或治疗免疫相关疾病以及改善与免疫相关病症相关的一种或多种症状中的用途。
-
公开(公告)号：US08012474B2
公开(公告)日：2011-09-06
申请号：US12221485
申请日：2008-08-04
IPC分类号： A61K39/395 , C07K16/18 , C07K16/24
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/52 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2319/00
摘要： The invention relates to fully human monoclonal antibodies, and fragments thereof, that bind to the chemokine Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES, CCL5), thereby modulating the interaction between RANTES and one of more of its receptors, such as, e.g., CCR1, CCR3, CCR4 and CCR5, and/or modulating the biological activities of RANTES. The invention also relates to the use of these or any anti-RANTES antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder.
摘要翻译： 本发明涉及完全人单克隆抗体及其片段，其结合活化时调节的趋化因子，表达正常T细胞和分泌型（RANTES，CCL5），从而调节RANTES与其多个受体之一的相互作用， 例如CCR1，CCR3，CCR4和CCR5，和/或调节RANTES的生物学活性。 本发明还涉及这些或任何抗RANTES抗体在预防或治疗免疫相关疾病以及改善与免疫相关病症相关的一种或多种症状中的用途。
-
公开(公告)号：US20090148455A1
公开(公告)日：2009-06-11
申请号：US12221485
申请日：2008-08-04
IPC分类号： A61K39/395 , C07K2/00 , C07H21/00 , C07K16/18
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/52 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2319/00
摘要： The invention relates to fully human monoclonal antibodies, and fragments thereof, that bind to the chemokine Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES, CCL5), thereby modulating the interaction between RANTES and one of more of its receptors, such as, e.g., CCR1, CCR3, CCR4 and CCR5, and/or modulating the biological activities of RANTES. The invention also relates to the use of these or any anti-RANTES antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder.
摘要翻译： 本发明涉及完全人单克隆抗体及其片段，其结合活化时调节的趋化因子，表达正常T细胞和分泌型（RANTES，CCL5），从而调节RANTES与其多个受体之一的相互作用， 例如CCR1，CCR3，CCR4和CCR5，和/或调节RANTES的生物学活性。 本发明还涉及这些或任何抗RANTES抗体在预防或治疗免疫相关疾病以及改善与免疫相关病症相关的一种或多种症状中的用途。
-
公开(公告)号：US20120201826A1
公开(公告)日：2012-08-09
申请号：US13207774
申请日：2011-08-11
IPC分类号： A61K39/395 , A61P29/00 , A61P37/06 , C07K16/24 , A61P9/10
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/21 , C07K2317/30 , C07K2317/33 , C07K2317/52 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92 , C07K2319/00
摘要： The invention relates to fully human monoclonal antibodies, and fragments thereof, that bind to the chemokine Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES, CCL5), thereby modulating the interaction between RANTES and one of more of its receptors, such as, e.g., CCR1, CCR3, CCR4 and CCR5, and/or modulating the biological activities of RANTES. The invention also relates to the use of these or any anti-RANTES antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder.
摘要翻译： 本发明涉及完全人单克隆抗体及其片段，其结合活化时调节的趋化因子，表达正常T细胞和分泌型（RANTES，CCL5），从而调节RANTES与其多个受体之一的相互作用， 例如CCR1，CCR3，CCR4和CCR5，和/或调节RANTES的生物学活性。 本发明还涉及这些或任何抗RANTES抗体在预防或治疗免疫相关疾病以及改善与免疫相关病症相关的一种或多种症状中的用途。
-
公开(公告)号：US20100183554A1
公开(公告)日：2010-07-22
申请号：US12750385
申请日：2010-03-30
申请人： Bernard Mach , Yann Dean , Marie Kosco-Vilbois , Greg Elson , Nicolas Fischer , Olivier Leger
发明人： Bernard Mach , Yann Dean , Marie Kosco-Vilbois , Greg Elson , Nicolas Fischer , Olivier Leger
IPC分类号： A61K39/395 , A61K38/21 , C07K16/28
CPC分类号： C07K16/2809 , A61K39/3955 , A61K45/06 , C07K2317/21 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/74
摘要： The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
摘要翻译： 本发明涉及针对抗原CD3的抗体和这种抗体的用途。 特别地，本发明提供了完全针对CD3的人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 ，被提供。 还提供了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。
-
公开(公告)号：US20090169561A1
公开(公告)日：2009-07-02
申请号：US12072824
申请日：2008-02-28
IPC分类号： A61K39/395 , C07K16/18
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The invention relates to fully human antibodies, and fragments thereof, that bind to interferon-inducible-protein-10 (IP-10, CXCL10), thereby modulating the interaction between IP-10 and its receptor, CXCR3, and/or modulating the biological activities of IP-10. The invention also relates to the use of such anti-IP-10 antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder.
摘要翻译： 本发明涉及与干扰素诱导型蛋白-10（IP-10，CXCL10）结合的完全人抗体及其片段，从而调节IP-10与其受体CXCR3之间的相互作用和/或调节生物学 IP-10活动。 本发明还涉及这样的抗-IP-10抗体在预防或治疗免疫相关病症中以及改善与免疫相关病症相关的一种或多种症状的用途。
-
公开(公告)号：US08551478B2
公开(公告)日：2013-10-08
申请号：US12750385
申请日：2010-03-30
申请人： Bernard Mach , Yann Dean , Marie Kosco-Vilbois , Greg Elson , Nicolas Fischer , Olivier Leger
发明人： Bernard Mach , Yann Dean , Marie Kosco-Vilbois , Greg Elson , Nicolas Fischer , Olivier Leger
IPC分类号： A61K39/395
CPC分类号： C07K16/2809 , A61K39/3955 , A61K45/06 , C07K2317/21 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/74
摘要： The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
摘要翻译： 本发明涉及针对抗原CD3的抗体和这种抗体的用途。 特别地，本发明提供了完全针对CD3的人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 ，提供。 还提供了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。
-
公开(公告)号：US20130216549A1
公开(公告)日：2013-08-22
申请号：US13597644
申请日：2012-08-29
IPC分类号： C07K16/24
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The invention relates to fully human antibodies, and fragments thereof, that bind to interferon-inducible-protein-10 (IP-10, CXCL10), thereby modulating the interaction between IP-10 and its receptor, CXCR3, and/or modulating the biological activities of IP-10. The invention also relates to the use of such anti-IP-10 antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder.
摘要翻译： 本发明涉及与干扰素诱导型蛋白-10（IP-10，CXCL10）结合的完全人抗体及其片段，从而调节IP-10与其受体CXCR3之间的相互作用和/或调节生物学 IP-10活动。 本发明还涉及这样的抗-IP-10抗体在预防或治疗免疫相关病症中以及改善与免疫相关病症相关的一种或多种症状的用途。
-
公开(公告)号：US20060177896A1
公开(公告)日：2006-08-10
申请号：US11145131
申请日：2005-06-03
申请人： Bernard Mach , Yann Dean , Marie Kosco-Vilbois , Greg Elson , Nicolas Fischer , Olivier Leger
发明人： Bernard Mach , Yann Dean , Marie Kosco-Vilbois , Greg Elson , Nicolas Fischer , Olivier Leger
CPC分类号： C07K16/2809 , A61K39/3955 , A61K45/06 , C07K2317/21 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/74
摘要： The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
-
公开(公告)号：US08258267B2
公开(公告)日：2012-09-04
申请号：US12529124
申请日：2008-02-28
IPC分类号： A61K39/395 , A61K39/40 , C07K17/00
CPC分类号： C07K16/24 , A61K2039/505 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： The invention relates to fully human antibodies, and fragments thereof, that bind to interferon-inducible-protein-10 (IP-IO, CXCL1O), thereby modulating the interaction between IP-IO and its receptor, CXCR3, and/or modulating the biological activities of IP-IO. The invention also relates to the use of such anti-IP-10 antibodies in the prevention or treatment of immune-related disorders and in the amelioration of one or more symptoms associated with an immune-related disorder.
摘要翻译： 本发明涉及与干扰素诱导型蛋白-10（IP-10，CXCL10）结合的完全人抗体及其片段，从而调节IP-10与其受体CXCR3之间的相互作用和/或调节生物学 IP-IO的活动。 本发明还涉及这样的抗-IP-10抗体在预防或治疗免疫相关病症中以及改善与免疫相关病症相关的一种或多种症状的用途。
-
-
-
-
-
-
-
-
-
搜索结果
42 条记录 (耗时 0.029 秒)